The third quarter is "all about vaccines," saidEvercore ISI analyst Umer Raffat," Bloomberg reported on Wednesday.
AstraZeneca and Pfizer partnership with BioNTech will be among the most watched events in the quarter, he said, adding that while much of the focus is on larger companies, and smaller companies like Novavax and Inovio have faced some scepticism, it's not impossible that the smaller companies will find success.
According to Morgan Stanley, Merck & Co. is working with Ridgeback Biotherapeutics on EIDD-2801, an oral antiviral drug that may start late-stage studies in patients in July, with analyst David Risinger noting that since it's a pill, EIDD-2801 could be taken immediately after diagnosis.
Risinger sees "blockbuster potential" for the drug with a potential approval before the end of the year if larger trials are successful.
Meanwhile, Steven Seedhouse, an analyst with Raymond James, noted that Eli Lilly and Regeneron Pharmaceuticals' neutralising antibodies "could potentially 'bend the curve' of COVID-19 outcomes if they prove effective in treating early or mid-stage infections."
Goldman Sachs analyst Terence Flynn said that given the precedent set by remdesivir, these drugs could breeze through regulatory hurdles if they show "any clinical benefit with an acceptable safety profile."
To read more NewsPoints articles, click here.